Celularity Inc. · NASDAQ:CELU
Celularity — Investor Presentation (June 2023)
14 slides from Celularity's investor presentation, June 2023
Slide 1: The Next Evolution in Cellular Medicine
THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023 CONFIDENTIAL Page 1
Slide 2: Legal Disclaimers
LEGAL DISCLAIMERS All statements in this presentation other than statements of historical facts regarding Celularity Inc. (“Celularity”) are “forward-looking statements” reflecting management’s current beliefs and expectations, including those relating to future events. In some cases, you can identi
Slide 3: About Celularity
ABOUT CELULARITY Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial-based therapeutics products. • Our IMPACT platform capitalizes on the benefits of placental- derived stem, p
Slide 4: Celularity's Vision
CELULARITY’S VISION Mission Statement Deliver innovative off-the-shelf allogeneic cellular medicines and biomaterials for patients with high unmet need at unparalleled scale, quality and economics Lead the transformative potential of placental-derived therapeutics: advance the discovery of the place
Slide 5: Celularity: Company History
CELULARITY: COMPANY HISTORY Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation Fast Track and FIH cryopreserved Orphan New Data in Frontiers Placental-Derived allogeneic Designation by in Immunology Allogeneic Cell placental-derived the FDA for Demonstrating Therapy Pro
Slide 6: Our Experienced Leadership Team
OUR EXPERIENCED LEADERSHIP TEAM With Deep Expertise in Cell Therapy and Advanced Biomaterials Robert J. Hariri, M.D., Ph.D. John Haines Adrian Kilcoyne, Stephen Brigido, DPM David Beers, CFA M.D., M.P.H., M.B.A. Chairperson, Founder, & CEO Senior EVP, GM & Chief President, Degenerative Chief Financi
Slide 7: Celularity Placental-Derived Product Platform
CELULARITY PLACENTAL-DERIVED PRODUCT PLATFORM Leveraging the Benefits of Placental-Derived Cells and Biomaterials to Target Multiple Diseases T-Cell Isolation + Genetic Modification One Placenta → Many Patients Cryopreserved - On Demand • Universal donor material & Off-The-Shelf • No requirement for
Slide 8: Single-Source, Placental-Based Platform Driving Broad Pipeline
Manufacturing SINGLE-SOURCE, PLACENTAL-BASED PLATFORM DRIVING BROAD PIPELINE The Placenta Cell Biomaterials Therapy ALLOGENEIC SINGLE SOURCE CELL TYPES AND ADVANCED 7 KEY PROGRAMS > 7 INITIAL INDICATIONS MATERIAL BIOMATERIALS CYCART-19 NHL, MCL T-Cell CYCART-201 NHL, MCL Unmodified NK HER2+Tumors CY
Slide 9: Manufacturing Overview
MANUFACTURING OVERVIEW Fully Integrated, Purpose-Built Commercial Scale Manufacturing Site Including Translational Research & Biorepository Purpose Built Facility for Commercial-scale Cellular Therapeutic Manufacturing ▪ $80M investment in cGMP/cGTP manufacturing ▪ Enables greater control, efficienc
Slide 10: Cell Therapy Clinical Pipeline
CELL THERAPY Clinical Pipeline PRE-CLINICAL CLINICAL Hematological Platform Functionality Indication Discovery IND-Enabling Phase 1/2 Phase 2/3 Malignancies CYNK-001 pNK Unmodified AML IL15 + Marrow CYNK-301 pNK AML Homing + CAR CYCART-19 pT CD19 + TCR KO NHL, MCL CD16 + TCR KO + CYCART-201 pT NHL,
Slide 11: Degenerative Diseases: Advanced Biomaterial Products Pipeline
DEGENERATIVE DISEASES Advanced Biomaterial Products Pipeline Degenerative Diseases Indication Discovery Regulatory Brands Integumental Tissue Placental Connective Tissue Matrix 361 HCT/P Replacement Amniotic Membrane Allograft Wound Covering 361 HCT/P Tri-Layer Amniotic Membrane Allograft Wound Cove
Slide 12: Current Commercial Portfolio Degenerative Diseases
CURRENT COMMERCIAL PORTFOLIO DEGENERATIVE DISEASES Improving Patients Health with Placental-Derived Advanced Biomaterial Products Page 12
Slide 13: Degenerative Disease Portfolio
DEGENERATIVE DISEASE PORTFOLIO Commercial Opportunities Deliver Revenue • Biovance®: Intact, natural extracellular matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. • Biovance 3L: a trilayer human amniotic membrane produ
Slide 14: The Next Evolution in Cellular Medicine
THE NEXT EVOLUTION IN CELLULAR MEDICINE CONFIDENTIAL Page 14